NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AK-AVS™ aortic valve stenosis (AVS) screening software has been accepted into the U.S. Food and Drug Administration (FDA) Total Product Life Cycle Advisory Program (TAP) pilot. AK-AVS, which received FDA Breakthrough Device Designation in October 2024, is an ECG-based AI algorithm intended to aid in the diagnosis of moderate to severe aortic valve stenosis in adult patients 22 year
See full post here as originally published on this site
